ProfileGDS5678 / 1432725_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 52% 52% 51% 52% 54% 55% 52% 51% 52% 53% 52% 52% 52% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3805454
GSM967853U87-EV human glioblastoma xenograft - Control 23.2750452
GSM967854U87-EV human glioblastoma xenograft - Control 33.275652
GSM967855U87-EV human glioblastoma xenograft - Control 43.175751
GSM967856U87-EV human glioblastoma xenograft - Control 53.1997652
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4459154
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4676955
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.257352
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2109551
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2493652
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2748753
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2198552
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2909352
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2753952